Literature DB >> 21396217

Standardised second-line treatment of multidrug-resistant tuberculosis during pregnancy.

P Tabarsi1, A Moradi, P Baghaei, M Marjani, M Shamaei, N Mansouri, E Chitsaz, P Farnia, D Mansouri, M Masjedi, A Velayati.   

Abstract

We describe the efficacy and outcome of standardised second-line anti-tuberculosis (TB) medications during pregnancy. Treatment outcomes of five pregnant women with documented multidrug-resistant TB (MDR-TB) referred to the National Research Institute of Tuberculosis and Lung Diseases from 2003 to 2009 were analysed in two categories, maternal and neonatal. Patients became pregnant during treatment for MDR-TB without any changes in their anti-tuberculosis regimen. None of them had any adverse effects during pregnancy and delivery. No adverse effects were observed in mothers or neonates. The treatment of MDR-TB during pregnancy with a standardised second-line regimen in this study population was safe, with an acceptable rate of treatment success.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21396217     DOI： 10.5588/ijtld.10.0140

Source DB:  PubMed          Journal:  Int J Tuberc Lung Dis        ISSN： 1027-3719            Impact factor:   2.373


  11 in total

Review 1.  Clinical Pharmacokinetics and Pharmacodynamics of Anti-Tubercular Drugs in Pregnancy.

Authors:  Jennifer R Shiu; Alan Min; Tony K L Kiang
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2021-01       Impact factor: 2.441

2.  Treatment of Drug-Resistant Tuberculosis. An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline.

Authors:  Payam Nahid; Sundari R Mase; Giovanni Battista Migliori; Giovanni Sotgiu; Graham H Bothamley; Jan L Brozek; Adithya Cattamanchi; J Peter Cegielski; Lisa Chen; Charles L Daley; Tracy L Dalton; Raquel Duarte; Federica Fregonese; C Robert Horsburgh; Faiz Ahmad Khan; Fayez Kheir; Zhiyi Lan; Alfred Lardizabal; Michael Lauzardo; Joan M Mangan; Suzanne M Marks; Lindsay McKenna; Dick Menzies; Carole D Mitnick; Diana M Nilsen; Farah Parvez; Charles A Peloquin; Ann Raftery; H Simon Schaaf; Neha S Shah; Jeffrey R Starke; John W Wilson; Jonathan M Wortham; Terence Chorba; Barbara Seaworth
Journal:  Am J Respir Crit Care Med       Date:  2019-11-15       Impact factor: 21.405

3.  Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis.

Authors:  Payam Nahid; Susan E Dorman; Narges Alipanah; Pennan M Barry; Jan L Brozek; Adithya Cattamanchi; Lelia H Chaisson; Richard E Chaisson; Charles L Daley; Malgosia Grzemska; Julie M Higashi; Christine S Ho; Philip C Hopewell; Salmaan A Keshavjee; Christian Lienhardt; Richard Menzies; Cynthia Merrifield; Masahiro Narita; Rick O'Brien; Charles A Peloquin; Ann Raftery; Jussi Saukkonen; H Simon Schaaf; Giovanni Sotgiu; Jeffrey R Starke; Giovanni Battista Migliori; Andrew Vernon
Journal:  Clin Infect Dis       Date:  2016-08-10       Impact factor: 9.079

Review 4.  Management of drug-resistant tuberculosis in special sub-populations including those with HIV co-infection, pregnancy, diabetes, organ-specific dysfunction, and in the critically ill.

Authors:  Aliasgar Esmail; Natasha F Sabur; Ikechi Okpechi; Keertan Dheda
Journal:  J Thorac Dis       Date:  2018-05       Impact factor: 2.895

Review 5.  Tuberculosis care for pregnant women: a systematic review.

Authors:  Hang Thanh Nguyen; Chiara Pandolfini; Peter Chiodini; Maurizio Bonati
Journal:  BMC Infect Dis       Date:  2014-11-19       Impact factor: 3.090

6.  Healthcare Provider Discrimination toward Pregnant Women with Rifampin-Resistant Tuberculosis.

Authors:  Marian Loveday; Sindisiwe Hlangu; Jennifer Furin
Journal:  Emerg Infect Dis       Date:  2019-03       Impact factor: 6.883

7.  "Take the treatment and be brave": Care experiences of pregnant women with rifampicin-resistant tuberculosis.

Authors:  Marian Loveday; Sindisiwe Hlangu; Jennifer Furin
Journal:  PLoS One       Date:  2020-12-21       Impact factor: 3.240

8.  Tuberculosis clinical presentation and treatment outcomes in pregnancy: a prospective cohort study.

Authors:  Brittney J van de Water; Meredith B Brooks; Chuan-Chin Huang; Letizia Trevisi; Leonid Lecca; Carmen Contreras; Jerome Galea; Roger Calderon; Rosa Yataco; Megan Murray; Mercedes C Becerra
Journal:  BMC Infect Dis       Date:  2020-09-18       Impact factor: 3.090

9.  Examining family planning and adverse pregnancy outcomes for women with active tuberculosis disease: a systematic review.

Authors:  Yen Nguyen; Katherine C McNabb; Jason E Farley; Nicole Warren
Journal:  BMJ Open       Date:  2022-03-28       Impact factor: 3.006

10.  Management of patients with multidrug-resistant/extensively drug-resistant tuberculosis in Europe: a TBNET consensus statement.

Authors:  Christoph Lange; Ibrahim Abubakar; Jan-Willem C Alffenaar; Graham Bothamley; Jose A Caminero; Anna Cristina C Carvalho; Kwok-Chiu Chang; Luigi Codecasa; Ana Correia; Valeriu Crudu; Peter Davies; Martin Dedicoat; Francis Drobniewski; Raquel Duarte; Cordula Ehlers; Connie Erkens; Delia Goletti; Gunar Günther; Elmira Ibraim; Beate Kampmann; Liga Kuksa; Wiel de Lange; Frank van Leth; Jan van Lunzen; Alberto Matteelli; Dick Menzies; Ignacio Monedero; Elvira Richter; Sabine Rüsch-Gerdes; Andreas Sandgren; Anna Scardigli; Alena Skrahina; Enrico Tortoli; Grigory Volchenkov; Dirk Wagner; Marieke J van der Werf; Bhanu Williams; Wing-Wai Yew; Jean-Pierre Zellweger; Daniela Maria Cirillo
Journal:  Eur Respir J       Date:  2014-03-23       Impact factor: 16.671
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.